araag2/HINT huggingface dataset:
Clinical trial NCT00648895 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: nebivolol, metoprolol er (tm)
SMILES: OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, ambulatory outpatients 18-79 years old at screening

          -  Minimum 2-year history of Stage I/II hypertension

          -  Qualifying blood pressure criteria for study entry and for randomization

          -  Willing to adhere to the dietary compliance and undergo protocol procedures

          -  Have a lifestyle that will permit him/her to attend all evaluations, including those
             conducted on consecutive days

        Exclusion Criteria:

          -  Have any form of secondary hypertension

          -  Have clinically significant respiratory or cardiovascular disease

          -  Presence/history of coronary artery disease or peripheral vascular disease

          -  Have diabetes mellitus, Type I or II

          -  Have a history of hypersensitivity to nebivolol, metoprolol, or any beta-blocker
Clinical trial NCT00174382 (phase 3, status: terminated)
Conditions: dementia, vascular, dementia, mixed
ICD codes: F01.50, F01.51, G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: donepezil
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1
Reason stopped: 
    see detailed description
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must meet DSM-IV-TR criteria for the clinical diagnosis of Vascular Dementia
             or the clinical diagnosis of dementia due to multiple etiologies.

          -  Subjects must have a reliable caregiver or family member who agrees to accompany the
             subject to all scheduled visits, provide information about the subject as required.

        Exclusion Criteria:

          -  Subjects with any current primary psychiatric diagnosis other than dementia of the
             Alzheimer's type or Vascular Dementia.
Clinical trial NCT01556997 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: xoma 985, amlodipine besylate, perindopril erbumine
SMILES: CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, [H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Essential hypertension

          -  For female subjects, a negative serum pregnancy test

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Night shift workers whose work hours include midnight to 4:00 a.m.

          -  Secondary hypertension

          -  An arm size that precludes the use of the digital blood pressure monitor cuff (arm
             size > 42 cm)

          -  Renal dysfunction, severe renal impairment, bilateral renal artery stenosis, renal
             artery stenosis in a solitary kidney, subjects with only 1 kidney, or post-renal
             transplant subjects

          -  Female subjects who are pregnant, planning to become pregnant

          -  History of malignancy within 5 years

          -  Primary aldosteronism

          -  Heart failure (NYHA functional class 3-4), hypertrophic obstructive cardiomyopathy, or
             hemodynamically relevant stenosis of the aortic or mitral valve

          -  Significant cardiac arrhythmias, MI, stroke, CABG, PTCA, unstable angina

          -  Known hypersensitivity to any component of the study drugs

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00445679 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: dvs sr, paroxetine
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Primary Inclusion Criteria:

          1. Outpatient men and women at least 18 years of age.

          2. Have a primary diagnosis of MDD based on the criteria in the Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition (DSM IV), single or recurrent
             episode, without psychotic features.

          3. Have a HAM D17 total score ≥20 at the screening and baseline (study day 1) visit.

        Primary Exclusion Criteria:

          1. Treatment with DVS SR at any time in the past.

          2. Significant risk of suicide based on clinical judgment, including common suicidal
             thoughts and suicide having been considered as a possible solution even without
             specific plans or intent.

          3. Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled
             hypertension), ophthalmologic, neurologic, or any other medical condition that might
             confound the study or put the subject at greater risk during study participation.
Clinical trial NCT01369615 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: oxycodone hydrochloride controlled-release tablets
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
Eligibility criteria:

        Inclusion Criteria include:

          1. Male and female patients aged 6 to 17 years, inclusive, who completed the 4-week study
             drug treatment in study OTR3001 and who, based on the investigator's judgment, will
             benefit from continuing treatment with oxycodone HCl CR 20 to 240 mg/day for the
             management of moderate to severe malignant or nonmalignant pain;

          2. Patients must have tolerated the oxycodone HCl CR therapy in OTR3001 as demonstrated
             at the start of the study;

          3. Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.

        Exclusion Criteria include:

          1. Patients with ongoing adverse events in OTR3001 that, in the investigator's opinion,
             disqualify them from participation in the study;

          2. Female patients who are pregnant or lactating;

          3. Patients requiring opioid at doses equivalent to < 20 mg/day or > 240 mg/day oxycodone
             for treatment of their malignant or nonmalignant pain;

          4. Patients who are allergic to oxycodone or have a history of allergies to other opioids
             (this criterion does not include patients who have experienced common opioid side
             effects [eg, nausea, constipation]);

          5. Patients who are contraindicated for the use of opioids;

          6. Patients who are currently being maintained on methadone for pain;

          7. Patients who have an abnormality on vital signs, physical examination, or laboratory
             testing significant enough that the investigator deems the patient is not appropriate
             for the study;

          8. Patients who have any planned surgery during the course of the study, with the
             exception of the placement of central or peripheral venous access devices;

          9. Patients currently taking an investigational medication/therapy other than the study
             drug (oxycodone HCl CR) at the start of screening or during the study.

        Other protocol specific inclusion/exclusion criteria may apply.
Clinical trial NCT00299013 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: colal-pred®, prednisolone
SMILES: [Na+].CC12CC(O)C3C(CCC4=CC(=O)C=CC34C)C1CCC2(O)C(=O)COC(=O)C1=CC(=CC=C1)S([O-])(=O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Endoscopically confirmed diagnosis of ulcerative colitis

          -  Score of 6-10 on the Disease Activity Index (DAI)

          -  Moderate to severe mucosal appearance

        Exclusion Criteria:

          -  Previous colonic surgery

          -  Other treatments for ulcerative colitis that have not been stabilised

          -  Clinically significant diabetes, heart failure, unstable angina, cirrhosis, renal
             failure

          -  History of tuberculosis
Clinical trial NCT00622700 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: teriflunomide, placebo
SMILES: C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  First acute or subacute, well-defined neurological event consistent with demyelination
             (that is, optic neuritis confirmed by an ophthalmologist, spinal cord syndrome,
             brainstem/cerebellar syndromes)

          -  Onset of MS symptoms occurring within 90 days of randomization

          -  A screening MRI scan with 2 or more T2 lesions at least 3 millimeter (mm) in diameter
             that are characteristic of MS

        Exclusion Criteria:

          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major
             systemic disease

          -  Significantly impaired bone marrow function

          -  Pregnancy or nursing

          -  Alcohol or drug abuse

          -  Use of cladribine, mitoxantrone, or other immunosuppressant agents such as
             azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before
             enrollment

          -  Any known condition or circumstance that would prevent in the investigator's opinion
             compliance or completion of the study

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT00330681 (phase 3, status: completed)
Conditions: amyotrophic lateral sclerosis (als)
ICD codes: G12.21
Drugs: mci-186, placebo of mci-186
SMILES: CC1=NN(C(=O)C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who are defined as "definite ALS," "probable ALS" or
             "probable-laboratory-supported ALS," met diagnostic criteria revised EL Escorial for
             Airlie House.

          -  Patients who can eat a meal, excrete, or move with oneself alone, and do not need
             assistance in everyday life.

          -  Patients of less than 3 years after the onset of ALS.

          -  Patients whose progress of the condition during 12 weeks before administration meet
             other requirements.

        Exclusion Criteria:

          -  Patients judged to be inadequate to participate in this study by their physician,
             because those patients' general condition deteriorated to the point that they need to
             be hospitalized for severe hepatic disease, severe heart disease, severe renal disease
             and so on, or they need to be administered antibiotics to infection.

          -  Patients who complain the difficulty in breathing caused by deteriorating the
             respiratory function.

          -  Patients with such complications as Parkinson's disease, schizophrenia, dementia,
             renal failure, or other severe complication, and patients who have the anamnesis of
             hypersensitivity to edaravone.

          -  Pregnant, lactating, and probably pregnant patients, and patients who want to become
             pregnant, and patients who can not agree to contraception.

          -  Patients who have participated in other trials within 12 weeks before consent, or who
             are participating in other clinical trials at present.

          -  In addition to the above exclusion criteria, patients judged to be inadequate to
             participate in this study by their physician.
Clinical trial NCT00812266 (phase 3, status: terminated)
Conditions: extensive disease, first-line, small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: topotecan + cisplatin, etoposide + carboplatin
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed SCLC

          -  Extensive stage

          -  No prior chemotherapy

          -  WHO PS 0-3

          -  Adequate organ function (liver, kidney)

          -  Adequate hematology (bone marrow)

          -  Informed consent

        Exclusion Criteria:

          -  PS 4

          -  Inadequate organ function

          -  Uncontrolled infection

          -  Concomitant major medical contraindications
Clinical trial NCT02006706 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituximab [mabthera/rituxan], methotrexate, methylprednisolone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-80 years of age;

          -  rheumatoid arthritis after inadequate response to >=1 DMARD treatment;

          -  active disease;

          -  DMARDs other than methotrexate withdrawn for at least 4 weeks prior to start of study
             treatment.

        Exclusion Criteria:

          -  autoimmune disease other than rheumatoid arthritis;

          -  bone/joint surgery within 8 weeks prior to screening, or joint surgery planned within
             24 weeks of MabThera infusion;

          -  concurrent treatment with any DMARD or antiTNF-alfa;

          -  intra-articular or parenteral corticosteroids within 4 weeks prior to screening.
Clinical trial NCT00229970 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast sodium, comparator: placebo
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Adult Patients With Acute Asthma Attacks

        Exclusion Criteria:

          -  Patient Has Any Known Or Suspected, Acute Or Chronic Cause For Their Pulmonary
             Symptoms Other Than Asthma (E.G., Copd, Chronic Heart Failure, Etc.)

          -  Patient Has A Smoking History (20 Cigarettes Per Day) Of More Than 15 Years

          -  Patient Has A Disease Of The Cardiovascular, Hepatic, Renal, Hematologic Systems, Or
             Other Severe Disease
Clinical trial NCT00735371 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder (adhd)
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: ldx 30 mg, ldx 50 mg, ldx 70 mg, placebo
SMILES: C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet DSM-IV-TR criteria for a primary diagnosis of ADHD

          -  Baseline ADHD-RS-IV score >=28

          -  BP w/in 95th percentile for age, gender, and height

        Exclusion Criteria:

          -  Subject has controlled or uncontrolled comorbid psychiatric diagnosis

          -  Subject has conduct disorder

          -  Suicidal

          -  Under or overweight

          -  Concurrent chronic or acute illness that might confound results.
Clinical trial NCT01530594 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: lenalidomide/low dose dex, bortezomib/lenalidomide/ low dose dex, lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        1. Patients must have newly diagnosed multiple myeloma

          2. Patients must have received no prior chemotherapy for this disease. Patients must have
             received no prior radiotherapy to a large area of the pelvis (more than half of the
             pelvis). Prior steroid treatment is allowed provided treatment was not more than 2
             weeks in duration. Patients must not have received any prior treatment with bortezomib
             or lenalidomide.

          3. Patients must be ≥ 18 years of age at the time of registration.

          4. Patients must have a Zubrod Performance Status (PS) of 0 - 3

          5. Patients must have adequate marrow function as defined herein:

          6. Platelet count ≥ 80 x 103/mcL,

          7. ANC ≥ 1 x 103/mcL, and Hemoglobin (including patients who have been either transfused
             or treated with EPO) ≥ 9 g/dL.

          8. Institutions must submit a local cytogenetics report and FISH analysis report

          9. Patients with pathologic fractures, pneumonia at diagnosis or symptomatic
             hyperviscosity.

         10. Patients must have a calculated or measured creatinine clearance > 30 cc/min.

         11. Patients must not have uncontrolled, active infection requiring intravenous
             antibiotics

         12. Patients must not have any psychiatric illness

         13. Patients must not be Hepatitis B, Hepatitis C or HIV positive

         14. Patients must not have a history of cerebral vascular accident with persistent
             neurologic deficits.

         15. Patients must be able to take aspirin 325 mg daily

         16. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test

         17. No prior malignancy is allowed except for adequately treated basal cell (or squamous
             cell) skin cancer, in situ cervical cancer or other cancer for which the patient has
             been disease-free for five years.

         18. Patients must be offered participation in GEP molecular studies for the evaluation of
             genetic polymorphisms.
Clinical trial NCT00322452 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib, carboplatin, paclitaxel
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced Stage IIIB not amenable to local therapy or Stage IV (metastatic)
             NSCLC with adenocarcinoma histology.

          -  Never smokers or light ex-smokers.(ceased smoking at least 15 years before Day 1 of
             study treatment and 10 pack-years or fewer)

        Exclusion Criteria:

          -  Had prior chemotherapy, biological (including targeted therapies such as EGFR and
             vascular epidermal growth factor (VEGF) inhibitors) or immunological therapy.

          -  Pre-existing idiopathic pulmonary fibrosis evidence by CT scan at baseline.
Clinical trial NCT01106131 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ckd-501 0.5mg, pioglitazone 15mg
SMILES: COC1=CC=C(OC2=NC=NC(=C2)N(C)CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Between 18 years and 80 years old(male or female)

          -  Type Ⅱ diabetes mellitus

          -  The patient who has been taking oral hypoglycemic agent since 2 months with HbA1c 7 to
             10% at screening test

          -  BMI between 21kg/㎡ and 40kg/㎡

          -  C-peptide level is over 1.0 ng/ml

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Type I diabetes or secondary diabetes

          -  Continuous or non continuous treatment(over 7 days) insulin within 3 month prior to
             screening

          -  Treatment with thiazolidinediones within 60 days or patient who have experience such
             as hypersensitivity reaction, serious adverse event or no effect by treatment with
             glitazones

          -  Chronic(continuous over 7 days) oral or non oral corticosteroids treatment within 1
             month prior to screening

          -  Past history: lactic acidosis or metformin contraindication

          -  Acute or chronic metabolic acidosis including diabetic ketoacidosis

          -  History of proliferative diabetic retinopathy

          -  Severe infection, severe injury patients (pre and post operation)

          -  Oligotrophy,starvation, hyposthenia, pituitary insufficiency or capsular insufficiency

          -  Drug abuse or history of alcoholism

          -  History of myocardial infarction, heart failure, cerebral infarction, hematencephalon
             or unstable angina within 6 months

          -  Fasting Plasma Glucose level is over 270 mg/dl

          -  Triglyceride level is 500 mg/dl and over

          -  Significant abnormal liver dysfunction: AST, ALT level over or equal to 2.5 times,
             Total bilirubin level over or equal 2 times as high as upper normal limit(UNL)

          -  Significant abnormal renal dysfunction

          -  Anemia

          -  Abnormality of thyroid function(out of significant normal TSH range )

          -  Hepatitis B or C test is positive

          -  Pregnant women or nursing mothers

          -  Has a contraindication to treatment

          -  Fertile women who not practice contraception with appropriate methods

          -  Participated in other trial within 4 weeks

          -  Participating in other trial at present

          -  In investigator's judgment
Clinical trial NCT00568308 (phase 3, status: terminated)
Conditions: cancer, liver cancer, primary liver cancer, hepatocellular carcinoma, hepatoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6, C22.8, C22.9, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: pi-88, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    commercial decision to discontinue the study
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically-proven primary hepatocellular carcinoma with curative resection
             performed in the 4 - 6 weeks prior to randomisation.

          -  ECOG performance status 0 to 2

          -  Child Pugh classification A or B

        Key Exclusion Criteria:

          -  Any evidence of tumour metastasis or co-existing malignant disease

          -  Any prior recurrence of HCC or any liver resection prior to the most recent procedure

          -  History of prior HCC therapy